tirzepatide news november 2025 GLP-1 Pipeline Update: - Prime Therapeutics Massive sales for weight loss

Mona spoy bezporednio lub rozcieczy w wodzie

& Maier, C

In a prospective open-label pilot study by Krajnc et al., patients had chronic IIH under treatment (some had persistent papilledema ~ 70% at baseline) [27]

Additionally, this modification addressed MIPS eligible clinicians' concerns that cost measure scoring negatively impacts their final scores more than other performance categories, including disparate negative effects for MIPS eligible clinicians who are scored on the cost performance category compared to clinicians not scored on the cost performance category (89 FR 98443)

Together, these elements support durable improvements in metabolic health